[{"id":"4a813da5-297d-49ae-9882-067e74ae69db","acronym":"STESIDES","url":"https://clinicaltrials.gov/study/NCT03878823","created_at":"2021-01-18T19:07:24.027Z","updated_at":"2024-07-02T16:35:21.379Z","phase":"Phase 1/2","brief_title":"Safety and Pharmacokinetics of ODM-209","source_id_and_acronym":"NCT03878823 - STESIDES","lead_sponsor":"Orion Corporation, Orion Pharma","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ODM-209"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 04/17/2019","start_date":" 04/17/2019","primary_txt":" Primary completion: 01/09/2024","primary_completion_date":" 01/09/2024","study_txt":" Completion: 01/09/2024","study_completion_date":" 01/09/2024","last_update_posted":"2024-02-01"},{"id":"ed788d65-0132-4f88-b51e-b0cbc192fc90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638763","created_at":"2022-12-06T15:57:59.939Z","updated_at":"2024-07-02T16:35:59.603Z","phase":"Phase 2","brief_title":"Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT05638763","lead_sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2022-12-06"}]